Accession Number:

ADA612754

Title:

Targeting Nuclear FGF Receptor to Improve Chemotherapy Response in Triple-Negative Breast Cancer

Descriptive Note:

Annual rept. 30 Sep 2013-29 Sep 2014

Corporate Author:

DUKE UNIV DURHAM NC

Personal Author(s):

Report Date:

2014-10-01

Pagination or Media Count:

23.0

Abstract:

During this funding period, we determined an optimal window of time 8 days post chemotherapy-treatment in which to study chemo-resistance signaling in chemo-residual triple-negative tumor cells, establishing an in vitro model of triple-negative breast cancer dormancyrecurrence. This work resulted in a manuscript publication. Using this model, we investigated the effect of reducing FGF receptor 2 expression in TN tumor cells on their chemo-resistance. This data showed that FGFR2 does not drive chemoresistance in this breast cancer sub-type, disproving our original hypothesis. Using a Novartis FGFR inhibitor, we confirmed a role for FGFR family members in TN tumor resistance, and obtained new data implicating FGF receptor 3 in this function. These data provide a foundation for testing FGFR3 regulation of TN tumor cell chemo-resistance in the next grant period.

Subject Categories:

  • Biology
  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE